1. Reversal of nonarteritic anterior ischemic optic neuropathy associated with coexisting primary antiphospholipid syndrome and Factor V Leiden mutation
- Author
-
Mark D McColl, W.H Watson, Alistair Fern, and Sathish Srinivasan
- Subjects
medicine.medical_specialty ,genetic structures ,Eye disease ,Enzyme-Linked Immunosorbent Assay ,Polymerase Chain Reaction ,Optic neuropathy ,Internal medicine ,medicine ,Factor V Leiden ,Humans ,Point Mutation ,Optic Neuropathy, Ischemic ,cardiovascular diseases ,Activated Protein C Resistance ,Arteritis ,business.industry ,Warfarin ,Anticoagulants ,Factor V ,Ischemic optic neuropathy ,Heparin, Low-Molecular-Weight ,Middle Aged ,medicine.disease ,Antiphospholipid Syndrome ,Thrombosis ,eye diseases ,Surgery ,Ophthalmology ,Optic nerve ,Cardiology ,Anterior ischemic optic neuropathy ,Female ,business ,medicine.drug - Abstract
PURPOSE: To report nonarteric anterior ischemic optic neuropathy (NAION) as an ocular manifestation in a woman with combined primary antiphospholipid syndrome and Factor V Leiden (FVL) mutation. METHODS: Case report of a middle-aged woman with hematological investigations confirming the diagnosis of both primary antiphospholipid syndrome and Factor V Leiden mutation, who presented with visual disturbance in her left eye. RESULTS: NAION was noted in her left eye. The patient was promptly treated with low molecular weight heparin, followed by warfarin, which resulted in the reversal of the ischemic optic neuropathy. CONCLUSIONS: Primary antiphospholipid syndrome and coexisting Factor V Leiden mutation should be considered in the differential diagnosis of NAION. Prompt treatment with anticoagulants can result in the reversal of the ischemic process.
- Published
- 2001